PT2892560T - Métodos e produtos para prevenção e/ou tratamento do cancro metastático - Google Patents
Métodos e produtos para prevenção e/ou tratamento do cancro metastáticoInfo
- Publication number
- PT2892560T PT2892560T PT138351218T PT13835121T PT2892560T PT 2892560 T PT2892560 T PT 2892560T PT 138351218 T PT138351218 T PT 138351218T PT 13835121 T PT13835121 T PT 13835121T PT 2892560 T PT2892560 T PT 2892560T
- Authority
- PT
- Portugal
- Prior art keywords
- preventing
- products
- methods
- metastatic cancer
- treating metastatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012903874A AU2012903874A0 (en) | 2012-09-06 | Methods and products for preventing and/or treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2892560T true PT2892560T (pt) | 2019-10-18 |
Family
ID=50236380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT138351218T PT2892560T (pt) | 2012-09-06 | 2013-09-06 | Métodos e produtos para prevenção e/ou tratamento do cancro metastático |
Country Status (7)
Country | Link |
---|---|
US (2) | US9718887B2 (pt) |
EP (1) | EP2892560B1 (pt) |
CN (2) | CN104884087B (pt) |
AU (3) | AU2013313026A1 (pt) |
ES (1) | ES2747836T3 (pt) |
PT (1) | PT2892560T (pt) |
WO (1) | WO2014036608A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014165916A1 (en) * | 2013-04-10 | 2014-10-16 | Adelaide Research & Innovation Pty Ltd | Methods and compositions for inducing an immune response |
CN107429249B (zh) * | 2015-12-29 | 2021-04-09 | 深圳先进技术研究院 | 雌性生殖疾病靶点cmklr1及其拮抗剂与相关应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
DE19715504C2 (de) * | 1997-04-14 | 2000-10-26 | Max Planck Gesellschaft | PMMA-Membranen mit Polyethylenglykol-gekoppelten Wirksubstanzen |
US6835547B1 (en) * | 1999-10-12 | 2004-12-28 | Chemocentryx, Inc. | Methods for identifying modulators of CCX CKR activity |
US6998239B1 (en) * | 1999-10-12 | 2006-02-14 | Chemocentryx, Inc. | Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine |
ES2339326T3 (es) | 1999-10-12 | 2010-05-19 | Chemocentryx, Inc. | Receptor de quimioquina. |
US6699677B1 (en) | 1999-12-20 | 2004-03-02 | Chemocentryx, Inc. | Tethered ligands and methods of use |
WO2001066598A2 (en) | 2000-03-03 | 2001-09-13 | Icos Corporation | Chemoattractant receptor characterization and cell selection materials and methods and chemokine receptor ccr11 materials and methods |
AU2001250412A1 (en) | 2000-03-31 | 2001-10-08 | Ipf Pharmaceuticals Gmbh | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US20120064089A1 (en) | 2002-11-15 | 2012-03-15 | Morehouse School Of Medicine | Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration |
US20050176073A1 (en) | 2004-02-06 | 2005-08-11 | Chemocentryx, Inc. | Cell proliferation associated with CCX CKR expression |
JP2011522801A (ja) | 2008-05-22 | 2011-08-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | CCR10のα−置換N−スルホニルグリシン(GYLCINE)アミドアンタゴニスト、それらを含有する組成物およびそれらを使用するための方法 |
-
2013
- 2013-09-06 CN CN201380058084.8A patent/CN104884087B/zh active Active
- 2013-09-06 US US14/426,534 patent/US9718887B2/en active Active
- 2013-09-06 CN CN201910562555.8A patent/CN110251674A/zh active Pending
- 2013-09-06 PT PT138351218T patent/PT2892560T/pt unknown
- 2013-09-06 ES ES13835121T patent/ES2747836T3/es active Active
- 2013-09-06 EP EP13835121.8A patent/EP2892560B1/en active Active
- 2013-09-06 AU AU2013313026A patent/AU2013313026A1/en not_active Abandoned
- 2013-09-06 WO PCT/AU2013/001014 patent/WO2014036608A1/en active Application Filing
-
2017
- 2017-07-21 US US15/656,611 patent/US20180022818A1/en not_active Abandoned
-
2018
- 2018-04-03 AU AU2018202318A patent/AU2018202318B2/en not_active Ceased
-
2020
- 2020-01-28 AU AU2020200574A patent/AU2020200574B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO2014036608A1 (en) | 2014-03-13 |
US9718887B2 (en) | 2017-08-01 |
EP2892560B1 (en) | 2019-07-03 |
CN104884087A (zh) | 2015-09-02 |
US20180022818A1 (en) | 2018-01-25 |
CN104884087B (zh) | 2019-07-30 |
ES2747836T3 (es) | 2020-03-11 |
US20150291698A1 (en) | 2015-10-15 |
AU2020200574B2 (en) | 2022-03-24 |
AU2018202318B2 (en) | 2020-02-13 |
AU2018202318A1 (en) | 2018-04-26 |
EP2892560A4 (en) | 2016-03-23 |
AU2020200574A1 (en) | 2020-02-13 |
AU2013313026A1 (en) | 2015-04-16 |
CN110251674A (zh) | 2019-09-20 |
EP2892560A1 (en) | 2015-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1209798A1 (en) | Compositions and methods for treating cancer | |
EP2836482A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
IL245281A0 (en) | Methods and preparations for the treatment of cancer | |
EP2890720A4 (en) | COMPOSITIONS AND METHODS OF TREATING CANCER | |
HK1206431A1 (en) | Method for the prognosis and treatment of cancer metastasis | |
EP2861256A4 (en) | COMPOSITIONS FOR THE TREATMENT OF CANCER AND METHODS FOR PREPARING THE SAME | |
PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
IL244353A0 (en) | Compounds and use for cancer treatment | |
HK1210049A1 (en) | Combination therapies for treating cancer | |
HK1206352A1 (en) | Means and method for treating solid tumours | |
HK1216854A1 (zh) | 用於治療癌症的組合物和方法 | |
HK1210136A1 (en) | Ingenol-derived compounds that can be used for treating cancer | |
EP2825693A4 (en) | METHOD AND MATERIALS FOR THE TREATMENT OF CANCER | |
EP2828664A4 (en) | METHODS OF TREATMENT AND MONITORING THE STATE OF CANCER | |
SG11201502584XA (en) | Peptides and methods for treating cancer | |
EP2533806A4 (en) | METHODS AND MATERIALS FOR TREATING CANCER | |
ZA201406172B (en) | Compounds and methods for treating leukemia | |
EP2846807C0 (en) | METHOD AND COMPOUNDS FOR INHIBITION OF MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT | |
EP2892560A4 (en) | METHODS AND PRODUCTS FOR THE PREVENTION AND / OR TREATMENT OF METASTASIC CANCER | |
HK1207561A1 (en) | Compositions and methods for treating hepatocellular cancer | |
EP2841102A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
EP2822593A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
EP2971044A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
EP2709623A4 (en) | MEDICINES AND METHODS FOR TREATING CANCER |